CDKN2A and glioblastoma: Genomic profiling has defined GBM subgroups and identified alterations in the core signaling pathways that are associated with CDK, such as CDKN2A/B, TP53, PTEN, EGRF amplification, CDK amplification, and CDK6 amplification [7,8].